Case Report Open Access
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 16, 2022; 10(20): 6936-6943
Published online Jul 16, 2022. doi: 10.12998/wjcc.v10.i20.6936
Autosomal dominant osteopetrosis type II resulting from a de novo mutation in the CLCN7 gene: A case report
Xiu-Li Song, Hong Wang, Genetic Diagnostic Centre, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Li-Yuan Peng, Dao-Wen Wang, Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
ORCID number: Xiu-Li Song (0000-0001-9681-8787); Li-Yuan Peng (0000-0002-0813-1449); Dao-Wen Wang (0000-0002-9774-3980); Hong Wang (0000-0003-0320-9160).
Author contributions: Song XL and Peng LY reviewed the literature and drafted the manuscript; Song XL and Wang H performed the whole-exome sequencing; Wang DW and Wang H were responsible for the revision of the manuscript for important intellectual content; all authors issued final approval for the version to be submitted.
Informed consent statement: Written informed consent was obtained from the patient’s legal guardian(s) for publication of this case report and any accompanying images.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hong Wang, PhD, Genetic Diagnostic Centre, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China. alextowh@163.com.
Received: September 15, 2021
Peer-review started: September 15, 2021
First decision: November 17, 2021
Revised: December 1, 2021
Accepted: May 28, 2022
Article in press: May 28, 2022
Published online: July 16, 2022

Abstract
BACKGROUND

Osteopetrosis is a family of extremely rare diseases caused by failure of osteoclasts and impaired bone resorption. Among them, autosomal dominant osteopetrosis type II (ADO II), related to the chloride channel 7 (CLCN7) gene, is the most frequent form of osteopetrosis. In this study, we report a de novo mutation of CLCN7 in a patient without the family history of ADO II.

CASE SUMMARY

A 5-year-old Chinese boy with ADO II was found to have a de novo mutation in the CLCN7 gene [c.746C>T (p.P249L)]. Typical clinical manifestations, including thickening of the cortex of spinal bones and long bones, non-traumatic fracture of the femoral neck, and femoral head necrosis, were found in this patient. The patient is the first reported case of ADO II with the missense mutation c.746C>T (p.P249L) of the CLCN7 gene reported in China. We also review the available literature on ADO II-related CLCN7 mutations, including baseline patient clinical features, special clinical significance, and common mutations.

CONCLUSION

Our report will enrich the understanding of mutations in ADO II patients. The possibility of a de novo mutation should be considered in individuals who have no family history of osteopetrosis.

Key Words: Osteopetrosis, Chloride channel 7 gene, Autosomal dominant osteopetrosis type Ⅱ, Whole exome sequencing, Case report

Core Tip: Osteopetrosis is a family of extremely rare diseases caused by failure of osteoclast and impaired bone resorption. The 5-year-old Chinese boy presented here is the first reported case of autosomal dominant osteopetrosis type II (ADO II) with the missense mutation c.746C>T (p.P249L) of the chloride channel 7 (CLCN7) gene in China. CLCN7 mutations can be due to de novo variants or due to inherited variants. The possibility of a de novo mutation should be considered in individuals who have no osteopetrosis family history. Our study systematically reviews the mutations of CLCN7 in ADO II, thus expanding the thoughts of diagnosis and treatment of osteopetrosis.



INTRODUCTION

Osteopetrosis, a genetic disorder caused by osteoclast failure, is an extremely rare bone disease with an incidence of 1 in 250000 births[1,2]. According to the classification of the Nosology Group of the International Skeletal Dysplasia Society, osteopetrosis is divided into various types by their inheritance pattern and characteristics with various clinical features[3]. Among them, autosomal dominant osteopetrosis type II (ADO II) caused by mutations of the chloride channel 7 (CLCN7) gene, also called Albers-Schönberg disease, is considered the most heterogeneous and frequent form of osteopetrosis[2,4]. Despite most ADO patients having no symptoms, the increased density of bones may be discovered by coincidental radiographic examination for other reasons, such as fracture[5]. The major clinical features of this type of osteopetrosis include non-traumatic fractures, especially in long bones, abnormal side-to-side curvature of the spine, and osteomyelitis in late childhood or adolescence[6].

Here we report a 5-year-old Chinese boy with ADO II who was found to have a de novo mutation in the CLCN7 gene [c.746C>T (p.P249L)]. The patient showed typical clinical manifestations including a thickened cortex of spinal bones and long bones, non-traumatic fracture of the femoral neck, and femoral head necrosis. We also performed a comprehensive literature review to systematically review the CLCN7 gene mutation features of ADO II.

CASE PRESENTATION
Chief complaints

A 5-year-old boy complained of painless claudication for 1 mo.

History of present illness

The patient started to experience painless claudication without any trauma about 1 mo prior to attending our clinic. He had no symptoms of fever, nausea, or vomiting.

History of past illness

The patient had no history of hormone treatment or any chronic disease, such as hepatitis, diabetes, or hypertension. His parents had no history of bone fractures or other special family histories.

Personal and family history

The patient had no special personal and family history.

Physical examination

The joint activity of the right hip was limited, especially rotating action. The length of the two lower limbs was equal. In addition, the liver was slightly enlarged, extending 4.0 cm below the right costal margin. Spleen size was normal. On neurological examination, no specific findings were noted.

Laboratory examinations

There was no remarkable abnormality in serum biochemistry, other than elevated concentrations of creatine kinase, lactate dehydrogenase (LDH), and aspartate aminotransferase (AST) (Supplementary Table 1).

Imaging examinations

X-rays in a local clinic revealed a generalized increase in bone density. Pelvis X-rays, computed tomography, and magnetic resonance imaging scans revealed that thickening of the cortex and narrowing of the medullary cavity were found in the pelvis and bilateral femora, consistent with osteopetrosis. In addition, suspected bilateral femoral head necrosis and an old fracture of the right femoral neck were also found (Figure 1A-C). A chest X-ray showed increased bone density in the thoracic vertebrae, lumbar vertebrae, bilateral ribs, and bilateral humeri, with no obvious abnormalities in the lungs, heart, or septum (Figure 1D).

Figure 1
Figure 1 Diagnostic process. A-C: Pelvis X-ray (A), magnetic resonance imaging (B), and computed tomography (C) showed thickening of the cortex and narrowing of the medullary cavity in the pelvis and bilateral femurs. The neck of the right femoral head was irregular in shape and showed some free small bone shadow, suggesting the possibility of right femoral head and neck fracture (orange arrows); D and G: X-rays of the chest and right femur showed extensive bone density in the thoracic vertebrae, lumbar vertebrae, bilateral ribs, and bilateral humerus. There were no obvious abnormalities in the lungs, heart, or septum; E and F: Sanger sequencing to verify the heterozygous mutation of the CLCN7 gene (c.746C>T)
FINAL DIAGNOSIS

The final diagnosis of the presented case was ADO II (Figure 1E and F).

TREATMENT

After admission, the patient was treated by percutaneous traction and fixation of both lower limbs for 1 mo, and then discharged from our hospital.

OUTCOME AND FOLLOW-UP

No significant change was found in the pelvic X-ray at 1 mo after discharge. At the 2-year follow-up, a pelvic X-ray showed that the patient had recovered from a fracture of the right femoral neck, but widespread sclerosis of the right femur, thickened cortex, narrowed medullary cavity, and short femoral neck were still present, consistent with osteopetrosis (Figure 1G). Further follow-up is needed for a long-term prognosis.

DISCUSSION

Osteopetrosis is a disorder with symptoms including failure of osteoclasts and impaired bone resorption. The disorder is caused by mutations in at least 10 genes in humans[1,7]. The patient described in this report is the first case of ADO II with the missense mutation c.746C>T (p.P249L) of the CLCN7 gene reported in China. The genotype of the parents was wild-type, indicating that a de novo mutation was highly likely to affect protein function in this 5-year-old boy. The CLCN7 gene encodes chloride channel 7 (CLC-7), which plays a central role in the normal function of osteoclasts, and takes part in bone remodeling to ensure strong and healthy bones[8]. Mutations in the CLCN7 gene lead to the abnormal function of osteoclast-mediated extracellular acidification and disturb dissolution of the bone inorganic matrix, thus resulting in ADO II[1,9]. Among them, more than 70 different mutations in CLCN7 have been reported to be associated with ADO II[10].

CLCN7 is also regarded as the genetic basis of ADO II[1]. The symptoms and signs of osteopetrosis range widely in severity. In addition to the manifestations of ADO II, the boy reported in our study showed increased bone density, pathological fractures of bilateral femora, and modeling defects at the metaphyses, but no symptoms of osteomyelitis, diffuse or focal sclerosis, or dental abnormalities (including tooth eruption defects and dental caries). Besides, there was no hematological failure or cranial nerve compression in this boy.

We also conducted a literature search of PubMed, MedlinePlus, Embase, and Ovid databases from January 2004 to February 2021 using the following search terms: “CLCN7 gene” and “osteopetrosis” and “autosomal dominant osteopetrosis type II” without language restrictions. Finally, 21 published studies were identified as meeting the search criteria (Supplementary Figure 1). A summary of previous reported cases of ADO II patients as well as our case is provided in Table 1. In addition, several series of family studies are included[11-24]. Based on our summary of the literature, we found more female patients (53% of total) than males. There have been increasingly more studies on the gene mutations in ADO II since the year 2012. To date, nearly 40 mutations in CLCN7 have been identified linked to ADO II. As the gene expression profiles and characteristics of mutations are related to ethnic background, there have been more reports of CLCN7 mutations causing cases of ADO II in the Asian population than in Western countries over the last decades. These results help provide some clue to the analysis of the phenotype-genotype relationship.

Table 1 Characteristics of osteopetrosis patients with chloride channel 7 mutation from reported cases.
Ref.
Year
Country
Sex
Age (yr)
SNP property
Function change
Nucleotide change
Symptoms
Letizia et al[11]2004ItalyM16Exon 25 missenseA262D (p.Ala262Asp)788 C>ALumbar spine and pelvis pain; right ear deafness
Zhang et al[12]2009ChinaF32Exon 24 nonsenseR767W (p. Arg767Trp)2337C>TBack pain
M17Exon 25 frameshiftE798 FS (p.Glu798FS)60_61–/GBack pain
Xue et al[13]2012ChinaM28Exon16 missenseP470 L (p.Pro470Leu)1409 C>TRecurrent swelling in the right face; fractures of the legs; unerupted teeth with root dysplasia
M38Exon 10 missenseR286 W (p.Arg286Trp)856C>TOsteomyelitis; nonunion of a femur fracture; unerupted teeth with root dysplasia
Rashid et al[14]2013Iraqi-KurdishF12Exon 15 missenseR409 W (p.Arg409Trp)1225C>TAnemia; diffuse cutaneous ecchymosis with gum bleeding; recurrent epistaxis; chest infections; right-sided conductive deafness; back pain
M16Exon 15 nonsenseR409W (p.Arg409Trp)c.1225C>TDecline in visual acuity
Zheng et al[15]2014ChinaM51Exon 7 missenseG215 R (p.Gly215Arg)643 G>AFemur fracture
M12Exon 10 missenseA299V (p.Ala299Val)896C>TPain in the left foot
F75Exon 11 missenseW319R (p.Trp319Arg)955T>AClavicle fracture; knee osteoarthritis; anemia
Ozkan et al[16]2015TurkeyF46NaNANABack pain
Chen et al[17] 2016ChinaM43Exon 20 missenseP619 L (p.Pro619Leu)c.1856C>TDiscomfort in lower extremities
Piret et al[18]2016United KingdomF49Exon 20 missenseG215 R (p.Gly215Arg)c.643G>AFractures (tibia, ankle)
Zheng et al[19]2016ChinaM5Exon 4 missenseTyr99 Cys (p.Y99C)c.296 A>GFracture of the right clavicle
F35Exon 10 missenseV289L (p.Val289Leu)c.865G>CNA
F8-month-oldExon 17 missenseA542V (p.Ala542Val)c.1625C>TFlexion and abduction of the left hip was restricted
F27Exon 24 nonsenseR767W (p. Arg767Trp)c.2299C>TNeck discomfort
Zhang et al[20]2017ChinaM2Exon 9 missenseG240E (p.Gly240Glu)c.791G>ACompletely blind in his right eye
F5Exon 11 missenseF318S (p.Phe318Ser)c.953T>CPneumonia
F62Exon 24 nonsenseS753W (p.Ser753Trp)c.2258C>GBack pain
Kim et al[21]2018KoreaF68Exon 4 missenseY99C (p.Tyr99Cys)c.296A>GPain in hip joint; unable to walk independently
Kang et al[22]2019KoreaM18Exon 9 missenseP249 L (p.Pro249Leu)c.746C>TPain in the right shin
Li et al[23]2019ChinaF15Exon 9 missenseR286W (p.Arg286Trp)c.856C>TBack pain
F42Exon 22 missenseY746D (p.Try746Asp)c.2236T>GAnemia
M10Exon 3 missenseY99C (p.Tyr99Cys)c.296A>GRecurrent influenza; fractures in the left tibia
F32Exon 10 missenseE313K (p.Glu313Lys)c.937G>ABlind; fractures; tinnitus; splenomegaly
M24Exon 24 missenseG793R (p.Gly793Arg)c.2377G>CDiscomfort in the abdomen; fractures; cementoma; anemia; thrombocytopenia
F37Exon 16 missense; Exon 7 insertionP470L (p.Pro470Leu); p.Lys217Xc.1409C>T; c.647_648 dupTGGrowth retardation; cysts; recurrent infections of the right knee joint; arthralgia, ankylosis, deformity of the right knee with claudication; amblyopia of the left eye; amblyacousia of the left ear, dental problems, fracture, anemia
Peng et al[24]2020ChinaF22Intron 1 missenseM560V (p.Met560Val)c.1678A > GBone pain; fracture in the hip

Another reported de novo mutation, c.2144A>G (p.Tyr715Cys) change in CLCN7, appeared to be a gain-of-function variant[25]. In that case, both patients manifested developmental delay, organomegaly, and hypopigmentation resulting from lysosomal hyperacidity, abnormal storage, and enlarged intracellular vacuoles, but the patients were osteopetrosis-free. Functional study showed that p.Tyr715Cys was a gain-of-function CLCN7 variant. In our case, the patient manifested osteopetrosis which indicated the inactivating effect of the c.746C>T (p.P249L). However, further study is still needed to prove the loss-of-function mechanism caused by the mutation.

Due to the low incidence of osteopetrosis, it is often overlooked in daily clinical diagnosis. Most ADO II patients are diagnosed based on the typical clinical manifestations and presence of special radiological appearance, including thickening of the cortex and narrowing of the medullary cavity of vertebrae, ribs, and humerus[1,5,26], especially the presence of “sandwich vertebrae” and the “bone-within-bone” appearance of the iliac spine[26]. Almost 80% of osteopetrosis patients experience fractures, while 30% have hip osteoarthritis. However, ADO II patients might attend hospital just because of low back pain without any familial penetrance of the disease. Some special characteristics have been reported previously, including severe anemia, mild malocclusion with hypodontia, enamel dysplasia, right femur osteomyelitis, proximal renal tubular acidosis, renal stones, epilepsy, and blindness[18]. Biochemical markers have been considered for the diagnosis of osteopetroses, such as elevated creatine kinase MB isoenzyme (CK-MB), LDH, and AST[27,28]. However, considering the genetic heterogeneity of ADO II, next-generation sequencing (NGS) technology should be preferred during diagnostic examination.

By now, genetic testing has become widely used in the screening, diagnosis, and prognosis prediction of various diseases. In combination with clinical information, high-throughput DNA analysis according to whole-exome sequencing using NGS methods have been used to identify Mendelian disorders related to diseases and even to guide drug therapy[29]. In this case, even without the family history of ADO II, the possibility of a de novo mutation in the CLCN7 gene and subsequent ADO II cannot be ruled out. In addition to the conventional neurological, imaging, and biochemical examinations, whole-exome sequencing is critical for final diagnosis.

CONCLUSION

In summary, we describe the case of a 5-year-old Chinese boy with ADO II with a de novo mutation in the CLCN7 gene [c.746C>T (p.P249L)] and review the literature of CLCN7 gene related osteopetrosis cases reported before. To our knowledge, this is the first study that systematically reviews the mutations of CLCN7 in ADO II, which not only enriches the understanding of the pathogenesis of osteopetrosis but also expands the ideas on its diagnosis and treatment.

ACKNOWLEDGEMENTS

The authors thank the patient’s family for their cooperation.

Footnotes

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Genetics and heredity

Country/Territory of origin: China

Peer-review report’s scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Hosoya S, Japan; Tsou HK, Taiwan A-Editor: Lin FY, China S-Editor: Xing YX L-Editor: Wang TQ P-Editor: Xing YX

References
1.  Stark Z, Savarirayan R. Osteopetrosis. Orphanet J Rare Dis. 2009;4:5.  [PubMed]  [DOI]  [Cited in This Article: ]
2.  Del Fattore A, Cappariello A, Teti A. Genetics, pathogenesis and complications of osteopetrosis. Bone. 2008;42:19-29.  [PubMed]  [DOI]  [Cited in This Article: ]
3.  Superti-Furga A, Unger S. Nosology and classification of genetic skeletal disorders: 2006 revision. Am J Med Genet A. 2007;143A:1-18.  [PubMed]  [DOI]  [Cited in This Article: ]
4.  Bollerslev J. Autosomal dominant osteopetrosis: bone metabolism and epidemiological, clinical, and hormonal aspects. Endocr Rev. 1989;10:45-67.  [PubMed]  [DOI]  [Cited in This Article: ]
5.  Cleiren E, Bénichou O, Van Hul E, Gram J, Bollerslev J, Singer FR, Beaverson K, Aledo A, Whyte MP, Yoneyama T, deVernejoul MC, Van Hul W. Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet. 2001;10:2861-2867.  [PubMed]  [DOI]  [Cited in This Article: ]
6.  Bollerslev J. Osteopetrosis. A genetic and epidemiological study. Clin Genet. 1987;31:86-90.  [PubMed]  [DOI]  [Cited in This Article: ]
7.  Wada K, Harada D, Michigami T, Tachikawa K, Nakano Y, Kashiwagi H, Yamashita S, Sano T, Seino Y. A case of autosomal dominant osteopetrosis type II with a novel TCIRG1 gene mutation. J Pediatr Endocrinol Metab. 2013;26:575-577.  [PubMed]  [DOI]  [Cited in This Article: ]
8.  Schaller S, Henriksen K, Sørensen MG, Karsdal MA. The role of chloride channels in osteoclasts: ClC-7 as a target for osteoporosis treatment. Drug News Perspect. 2005;18:489-495.  [PubMed]  [DOI]  [Cited in This Article: ]
9.  Balemans W, Van Wesenbeeck L, Van Hul W. A clinical and molecular overview of the human osteopetroses. Calcif Tissue Int. 2005;77:263-274.  [PubMed]  [DOI]  [Cited in This Article: ]
10.  Bénichou O, Cleiren E, Gram J, Bollerslev J, de Vernejoul MC, Van Hul W. Mapping of autosomal dominant osteopetrosis type II (Albers-Schönberg disease) to chromosome 16p13.3. Am J Hum Genet. 2001;69:647-654.  [PubMed]  [DOI]  [Cited in This Article: ]
11.  Letizia C, Taranta A, Migliaccio S, Caliumi C, Diacinti D, Delfini E, D'Erasmo E, Iacobini M, Roggini M, Albagha OM, Ralston SH, Teti A. Type II benign osteopetrosis (Albers-Schönberg disease) caused by a novel mutation in CLCN7 presenting with unusual clinical manifestations. Calcif Tissue Int. 2004;74:42-46.  [PubMed]  [DOI]  [Cited in This Article: ]
12.  Zhang ZL, He JW, Zhang H, Hu WW, Fu WZ, Gu JM, Yu JB, Gao G, Hu YQ, Li M, Liu YJ. Identification of the CLCN7 gene mutations in two Chinese families with autosomal dominant osteopetrosis (type II). J Bone Miner Metab. 2009;27:444-451.  [PubMed]  [DOI]  [Cited in This Article: ]
13.  Xue Y, Wang W, Mao T, Duan X. Report of two Chinese patients suffering from CLCN7-related osteopetrosis and root dysplasia. J Craniomaxillofac Surg. 2012;40:416-420.  [PubMed]  [DOI]  [Cited in This Article: ]
14.  Rashid BM, Rashid NG, Schulz A, Lahr G, Nore BF. A novel missense mutation in the CLCN7 gene linked to benign autosomal dominant osteopetrosis: a case series. J Med Case Rep. 2013;7:7.  [PubMed]  [DOI]  [Cited in This Article: ]
15.  Zheng H, Zhang Z, He JW, Fu WZ, Wang C, Zhang ZL. Identification of two novel CLCN7 gene mutations in three Chinese families with autosomal dominant osteopetrosis type II. Joint Bone Spine. 2014;81:188-189.  [PubMed]  [DOI]  [Cited in This Article: ]
16.  Ozkan AK, Doruk P, Adam M, Celik ZY, Leblebici B. Autosomal Dominant Osteopetrosis Type II. J Back Musculoskelet Rehabil. 2015;28:197-200.  [PubMed]  [DOI]  [Cited in This Article: ]
17.  Chen X, Zhang K, Hock J, Wang C, Yu X. Enhanced but hypofunctional osteoclastogenesis in an autosomal dominant osteopetrosis type II case carrying a c.1856C>T mutation in CLCN7. Bone Res. 2016;4:16035.  [PubMed]  [DOI]  [Cited in This Article: ]
18.  Piret SE, Gorvin CM, Trinh A, Taylor J, Lise S, Taylor JC, Ebeling PR, Thakker RV. Autosomal dominant osteopetrosis associated with renal tubular acidosis is due to a CLCN7 mutation. Am J Med Genet A. 2016;170:2988-2992.  [PubMed]  [DOI]  [Cited in This Article: ]
19.  Zheng H, Shao C, Zheng Y, He JW, Fu WZ, Wang C, Zhang ZL. Two novel mutations of CLCN7 gene in Chinese families with autosomal dominant osteopetrosis (type II). J Bone Miner Metab. 2016;34:440-446.  [PubMed]  [DOI]  [Cited in This Article: ]
20.  Zhang X, Wei Z, He J, Wang C, Zhang Z. Novel mutations of CLCN7 cause autosomal dominant osteopetrosis type II (ADOII) and intermediate autosomal recessive osteopetrosis (ARO) in seven Chinese families. Postgrad Med. 2017;129:934-942.  [PubMed]  [DOI]  [Cited in This Article: ]
21.  Kim SY, Lee Y, Kang YE, Kim JM, Joung KH, Lee JH, Kim KS, Kim HJ, Ku BJ, Shong M, Yi HS. Genetic Analysis of CLCN7 in an Old Female Patient with Type II Autosomal Dominant Osteopetrosis. Endocrinol Metab (Seoul). 2018;33:380-386.  [PubMed]  [DOI]  [Cited in This Article: ]
22.  Kang S, Kang YK, Lee JA, Kim DH, Lim JS. A Case of Autosomal Dominant Osteopetrosis Type 2 with a CLCN7 Gene Mutation. J Clin Res Pediatr Endocrinol. 2019;11:439-443.  [PubMed]  [DOI]  [Cited in This Article: ]
23.  Li L, Lv SS, Wang C, Yue H, Zhang ZL. Novel CLCN7 mutations cause autosomal dominant osteopetrosis type II and intermediate autosomal recessive osteopetrosis. Mol Med Rep. 2019;19:5030-5038.  [PubMed]  [DOI]  [Cited in This Article: ]
24.  Peng H, He HB, Wen T. A Novel Variant in CLCN7 Regulates the Coupling of Angiogenesis and Osteogenesis. Front Cell Dev Biol. 2020;8:599826.  [PubMed]  [DOI]  [Cited in This Article: ]
25.  Nicoli ER, Weston MR, Hackbarth M, Becerril A, Larson A, Zein WM, Baker PR, 2nd, Burke JD, Dorward H, Davids M, Huang Y, Adams DR, Zerfas PM, Chen D, Markello TC, Toro C, Wood T, Elliott G, Vu M, Zheng W, Garrett LJ, Tifft CJ, Gahl WA, Day-Salvatore DL, Mindell JA, Malicdan MCV. Lysosomal Storage and Albinism Due to Effects of a De Novo CLCN7 Variant on Lysosomal Acidification. Am J Hum Genet. 2019;104:1127-1138.  [PubMed]  [DOI]  [Cited in This Article: ]
26.  Wu CC, Econs MJ, DiMeglio LA, Insogna KL, Levine MA, Orchard PJ, Miller WP, Petryk A, Rush ET, Shoback DM, Ward LM, Polgreen LE. Diagnosis and Management of Osteopetrosis: Consensus Guidelines From the Osteopetrosis Working Group. J Clin Endocrinol Metab. 2017;102:3111-3123.  [PubMed]  [DOI]  [Cited in This Article: ]
27.  Wang C, Zhang H, He JW, Gu JM, Hu WW, Hu YQ, Li M, Liu YJ, Fu WZ, Yue H, Ke YH, Zhang ZL. The virulence gene and clinical phenotypes of osteopetrosis in the Chinese population: six novel mutations of the CLCN7 gene in twelve osteopetrosis families. J Bone Miner Metab. 2012;30:338-348.  [PubMed]  [DOI]  [Cited in This Article: ]
28.  Whyte MP, Chines A, Silva DP, Jr. , Landt Y, Ladenson JH. Creatine kinase brain isoenzyme (BB-CK) presence in serum distinguishes osteopetroses among the sclerosing bone disorders. J Bone Miner Res11:1438-1443.  [PubMed]  [DOI]  [Cited in This Article: ]
29.  Franceschini N, Frick A, Kopp JB. Genetic Testing in Clinical Settings. Am J Kidney Dis. 2018;72:569-581.  [PubMed]  [DOI]  [Cited in This Article: ]